Optimalisation of the response to influenza virus vaccination in breast cancer and colorectal cancer patients immunocompromised due to chemotherapy.
- Conditions
- Vaccination, Influenza, Chemotherapy, breast cancer, colorectal cancer
- Registration Number
- NL-OMON20352
- Lead Sponsor
- niversity Medical Center
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 180
Inclusion Criteria
1. Patients with breast cancer treated FEC- or TAC-containing triweekly chemotherapy at moment of vaccination;
2. Patients with colorectal cancer treated with Oxaliplatin-containing triweekly chemotherapy at moment of vaccination;
Exclusion Criteria
1. Fever at time of vaccination defined as a temperature of > 38.5 C;
2. Previous/known allergic reaction to any of the components of the vaccines given, for example hypersensitivity to egg protein;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adequate rise in antibody titre.
- Secondary Outcome Measures
Name Time Method 1. Antibody titres against the influenza virus before and after vaccination;<br /><br>2. Ex vivo cellular immune response (cytokines, fine specificity) after vaccination.